Brian Gilmartin is a senior leader with more than 20 years of international experience spanning pharmaceutical product development, clinical strategy, operations and commercialisation.

His career began in early-stage drug discovery and bioinformatics within startup environments, followed by work on genome research initiatives, including at the University of Cambridge. He transitioned into the pharmaceutical industry in the mid-2000s, where he established deep expertise in regulatory affairs and technical operations, supporting end-to-end product development across CMC, nonclinical, and clinical domains.

Over the course of his career, Brian has worked across Europe, Asia-Pacific, Japan, US and Australia/New Zealand, providing him with a global perspective on regulatory frameworks and market access pathways. His experience includes leading regulatory strategy for new product registration, lifecycle management, and navigating complex cross-border development programs.

In the past decade, Brian has focused on bridging development and commercialisation by building and supporting pharmaceutical services across the JAPAC region. His work has enabled clinical trial supply, early access programs, unlicensed medicine pathways, and the successful commercialisation of innovative therapies addressing significant unmet medical needs.

Brian has extensive therapeutic expertise across haematology, oncology, cardiovascular disease, and rare diseases. He is particularly experienced in integrating regulatory strategy with clinical development planning and market access considerations to optimise product pathways from early development through to commercial launch.

As Director of Regulatory Affairs at Biointelect, Brian partners with biotechnology and pharmaceutical companies to design and execute global regulatory strategies, support clinical development planning, and enable efficient pathways to market—ensuring alignment between regulatory requirements, evidence generation, and commercial objectives.